Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as 10 mg Once-Daily Well-Tolerated Across All Doses Studied with an Adverse Event ...
Corvus Pharmaceuticals (NASDAQ:CRVS) provided an update on its pipeline at Oppenheimer’s Annual Healthcare Conference, with ...
Janux Therapeutics has dosed the first participant in a Phase I clinical trial of JANX011, a Cluster of Differentiation 19 ...
SHANNON, CLARE, IRELAND, February 27, 2026 /EINPresswire.com/ -- Announcing a new publication from Opto-Electronic ...
DURIPANC is an investigator-initiated, exploratory, open-label, single-center study, and 18 subjects have enrolled in the study so far. The clinical trial is a joint collaboration between AIM, ...
Helus Pharma (NASDAQ: HELP) is a clinical-stage pharmaceutical company developing treatments for depression and anxiety. Its ...
The evidence is solid but not definitive, as the conclusions rely on the absence of changes in spatial breadth and would benefit from clearer statistical justification and a more cautious ...
Funding to support the execution of a Phase 2 proof-of-concept trial of HER-096 in Parkinson’s disease, following completion of study ...
CNW/ - ("Devonian" or the Company) (TSXV: GSD) (OTCQB: DVHGF) today announced positive results from a follow-up preclinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results